Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388:2796–2810.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Capoun O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75–94.
   PubMed Web of Science ®Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline, 2016. Amended 2020 [Internet]. 2020 [cited 2023 Feb 3]. Available from: https://www.auanet.org/documents/education/clinical-guidance/Non-Muscle-Invasive-Bladder-Cancer.pdf
   Google Scholar
• NHS. Bladder cancer – Treatment [Internet]. 2017. [cited 2023 Feb 3]. Available from: https://www.nhs.uk/conditions/bladder-cancer/treatment/.
   Google Scholar
• NICE. Bladder cancer: diagnosis and management NICE guideline [NG2] [Internet]. 2015; [cited 2023 Mar 8]. Available from: https://www.nice.org.uk/guidance/ng2
   Google Scholar
• Leeds Teaching Hospitals. Urology, bladder problems [Internet]. [cited 2023 Feb 3]. Available from: https://www.leedsth.nhs.uk/a-z-of-services/urology/common-urological-conditions/bladder-cancer/.
   Google Scholar
• Kamat AM, Flaig TW, Grossman HB, et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12:225–235.
   PubMed Web of Science ®Google Scholar
• Lobo N, Brooks NA, Zlotta AR, et al. 100 Years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18:611–622.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Kunath F, Coles B, et al. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2020;1(1):CD011935.
   PubMedGoogle Scholar
• Mori K, Miura N, Babjuk M, et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review. Urol Oncol. 2020;38:774–782.
   PubMed Web of Science ®Google Scholar
• Mariappan P, Johnston A, Padovani L, et al. Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from Scotland’s quality performance indicators programme. Eur Urol. 2020;78:520–530.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment: guidance for industry [Internet]. Silver Spring (MD): US Department of Health and Human Services Food and Drug Administration; 2018 [cited 2023 Feb 3]. Available from: https://www.fda.gov/media/101468/download
   Google Scholar
• Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34:1935–1944.
   PubMed Web of Science ®Google Scholar
• Matulay JT, Li R, Hensley PJ, et al. Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with Bacillus Calmette-Guérin: implications for clinical trial design. J Urol. 2021;205:1612–1621.
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–338.
   PubMed Web of Science ®Google Scholar
• Witjes J, Bruins H, Carrión A, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer [Internet]. Amsterdam: European Association of Urology; 2022 [cited 2023 Mar 8]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-And-Metastatic-Bladder-Cancer-2022.pdf
   Google Scholar
• ICER. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value: final report [Internet]. Boston (MA): Institute for Clinical and Economic Review; 2020 [cited 2023 Mar 8]. Available from: https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf
   Google Scholar
• Sharma V, Wymer KM, Borah BJ, et al. Cost-effectiveness of maintenance bacillus Calmette-Guérin for intermediate and high risk nonmuscle invasive bladder cancer. J Urol. 2020;204:442–449.
   PubMed Web of Science ®Google Scholar
• Mossanen M, Wang Y, Szymaniak J, et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019;37:2059–2065.
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal 2013: process and methods (PMG9) [Internet]. London, Manchester: National Institute for Health and Care Excellence; 2013 [cited 2022 Dec 5]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
   Google Scholar
• Elshabrawy A, Wang H, Satsangi A, et al. Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer. Urol Oncol. 2021;39:236.e9–236.e20.
   PubMed Web of Science ®Google Scholar
• NICE. NICE health technology evaluations: the manual (PMG36) [Internet]. London (UK): National Institute for Health and Care Excellence; 2022 [cited 2023 Mar 8]. Available from: https://www.nice.org.uk/process/pmg36
   Google Scholar
• Gidwani R, Russell LB. Estimating transition probabilities from published evidence: a tutorial for decision modelers. Pharmacoeconomics. 2020;38:1153–1164.
   PubMed Web of Science ®Google Scholar
• Simon M, Bosset P-O, Rouanne M, et al. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PLOS One. 2019;14:e0211721.
   PubMed Web of Science ®Google Scholar
• Daniels MJ, Barry E, Schoenberg M, et al. Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol. 2020;38:5.e9–5.e16.
   PubMed Web of Science ®Google Scholar
• Diamant E, Roumiguié M, Ingels A, et al. Effectiveness of early radical cystectomy for high-risk non-muscle invasive bladder cancer. Cancers. 2022;14:3797.
   PubMed Web of Science ®Google Scholar
• Cheeseman S, Thompson M, Sopwith W, et al. Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre. Front Oncol. 2020;10:167.
   PubMed Web of Science ®Google Scholar
• Doisy L, Cimier A, Adypagavane A, et al. Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy. Int J Hyperthermia. 2021;38:1633–1638.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202–205. discussion 205–206.
   PubMed Web of Science ®Google Scholar
• ONS. National life tables – life expectancy in the UK: 2018 to 2020 [Internet]. Newport: Office for National Statistics; 2021 [cited 2022 Aug 30]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables
   Google Scholar
• Public Health England. Cancer survival in England for patients diagnosed between 2014 and 2018, and followed up until 2019 [Internet]. GOV.UK. 2020 [cited 2023 Mar 8]. Available from: https://www.gov.uk/government/statistics/cancer-survival-in-england-for-patients-diagnosed-between-2014-and-2018-and-followed-up-until-2019
   Google Scholar
• Cox E, Saramago P, Kelly J, et al. Effects of bladder cancer on UK healthcare costs and patient health-related quality of life: evidence from the BOXIT trial. Clin Genitourin Cancer. 2020;18:e418–e442.
   PubMed Web of Science ®Google Scholar
• Kulkarni GS, Finelli A, Fleshner NE, et al. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLOS Med. 2007;4:e284.
   PubMed Web of Science ®Google Scholar
• Mohiuddin S, Reeves BC, Smart NJ, et al. A semi-Markov model comparing the lifetime cost-effectiveness of mesh prophylaxis to prevent parastomal hernia in patients undergoing end colostomy creation for rectal cancer. Colorectal Dis. 2021;23:2967–2979.
   PubMed Web of Science ®Google Scholar
• Betts MB, Rane P, Bergrath E, et al. Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review. Health Qual Life Outcomes. 2020;18:251.
   PubMed Web of Science ®Google Scholar
• Fujii H, Ueda Y, Hirose C, et al. Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy. J Pharm Health Care Sci. 2022;8(1):8.
   PubMed Web of Science ®Google Scholar
• Stevenson SM, Danzig MR, Ghandour RA, et al. Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Urol Oncol. 2014;32:1172–1177.
   PubMed Web of Science ®Google Scholar
• Hagiwara Y, Shiroiwa T, Shimozuma K, et al. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36:215–223.
   PubMed Web of Science ®Google Scholar
• Hawe E, McBride D, Balp M-M, et al. EQ-5D utilities in chronic spontaneous/idiopathic urticaria. Pharmacoeconomics. 2016;34:521–527.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95:683–690.
   PubMed Web of Science ®Google Scholar
• Polotti C, Tan B, Borglum N, et al. Relationship between the Wisconsin stone quality of life (WISQOL) and preference-based/health utility measures of health-related quality of life (HRQoL) in kidney stone patients. Urology. 2020;141:33–38.
   PubMed Web of Science ®Google Scholar
• Liem YS, Bosch JL, Hunink MGM. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health. 2008;11:733–741.
   PubMed Web of Science ®Google Scholar
• Li B, Cairns JA, Fotheringham J, et al. Understanding cost of care for patients on renal replacement therapy: looking beyond fixed tariffs. Nephrol Dial Transplant. 2015;30:1726–1734.
   PubMedGoogle Scholar
• Armstrong N, Büyükkaramikli N, Penton H, et al. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2020;24:1–220.
   Web of Science ®Google Scholar
• National Clinical Guideline Centre (UK). Cost-effectiveness analysis – botulinum toxin type a versus augmentation cystoplasty [Internet]. London: Royal College of Physicians; 2012 (Report No. 148). [cited 2023 Mar 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK132839/
   Google Scholar
• Tawiah AK, Sayah A, Ohinmaa F, et al. Discriminative validity of the EQ-5D-5 L and SF-12 in older adults with arthritis. Health Qual Life Outcomes. 2019;17:68.
   PubMed Web of Science ®Google Scholar
• Kulkarni GS, Alibhai SMH, Finelli A, et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer. 2009;115:5450–5459.
   PubMed Web of Science ®Google Scholar
• emc. OncoTICE powder for instillation fluid for intravesical use - summary of product characteristics (SmPC) [Internet]. 2021. [cited 2022 Jun 23]. Available from: https://www.medicines.org.uk/emc/product/1049
   Google Scholar
• Magee D, Cheung D, Hird A, et al. Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a Markov microsimulation model. Can Urol Assoc J. 2022;16: E197–E204.
   PubMed Web of Science ®Google Scholar
• NHS England and NHS Improvement. 2022/23 National tariff payment system [Internet]. London: NHS England and NHS Improvement; 2022 [cited 2022 May 26]. Available from: https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/
   Google Scholar
• Office for National Statistics. CPI INDEX: medical services [Internet]. 2022 [cited 2022 Jun 26]. Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/dkc3/mm23
   Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–1129.
   PubMed Web of Science ®Google Scholar
• West Midlands Expert Advisory Group for Urological Cancer. Guidelines for the management of bladder cancer [Internet]. West Midlands Clinical Networks and Clinical Senate; 2019. [cited 2022 May 27]. Available from: https://www.england.nhs.uk/mids-east/wp-content/uploads/sites/7/2018/05/guidelines-for-the-management-of-bladder-cancer.pdf
   Google Scholar
• Niedersüss-Beke D, Puntus T, Kunit T, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer. Oncology. 2017;93:36–42.
   PubMed Web of Science ®Google Scholar
• emc. Gemcitabine 38 mg/ml concentrate for solution for infusion - summary of product characteristics (SmPC) [Internet]. 2022 [cited 2022 May 30]. Available from: https://www.medicines.org.uk/emc/product/4483/smpc
   Google Scholar
• West Midlands Cancer Alliance. Guidelines for G-CSF use [Internet]. Birmingham: West Midlands Cancer Alliance; 2021 [cited 2022 Nov 24]. Available from: https://wmcanceralliance.nhs.uk/images/WMCA_Guideline_for_Use_of_GCSF_Final_v1.0.pdf
   Google Scholar
• Sacco JJ, Botten J, Macbeth F, et al. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLOS One. 2010;5:e8933.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. UK health indicators [Internet]. 2022 [cited 2022 Jun 27]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/healthindicatorsfortheunitedkingdomanditsconstituentcountriesbasedonthe2013to2014europeanhealthinterviewsurveywave2
   Google Scholar
• Hugar LA, Lopa SH, Yabes JG, et al. Palliative care use amongst patients with bladder cancer. BJU Int. 2019;123:968–975.
   PubMed Web of Science ®Google Scholar
• Jones KC, Burns A. Unit costs of health and social care 2021. Kent (UK): Personal Social Services Research Unit; 2021.
   Google Scholar
• European Association Of Urology Research Foundation Türkeri LN, Babjuk MM. Treatment of high grade non-muscle invasive bladder carcinoma by standard number and dose of intravesical BCG instillations versus reduced number and dose of intravesical BCG instillations. A European Association of Urology Research Foundation randomised phase III clinical trial. Amsterdam: European Association of Urology Research Foundation; 2021.
   Google Scholar
• Grimm M-O, van der Heijden AG, Colombel M, et al. Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial “NIMBUS”. Eur Urol. 2020;78:690–698.
   PubMed Web of Science ®Google Scholar
• Jeglinschi S, Schirmann A, Durand M, et al. Factors affecting guideline adherence in the initial treatment of non-muscle invasive bladder cancer: retrospective study in a french peripheral hospital. Prog Urol. 2020;30:26–34.
   PubMed Web of Science ®Google Scholar
• Choo SH, Nishiyama H, Kitamura H, et al. Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: a web-based survey. Int J Urol. 2019;26:1121–1127.
   PubMed Web of Science ®Google Scholar
• Ferro M, Giudice D, Carrieri F, et al. The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: a retrospective multi-institutional cohort analysis. Cancers. 2021;13:5276.
   PubMed Web of Science ®Google Scholar
• Culpan M, Keser F, Acar HC, et al. Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non-muscle-invasive bladder cancer during the COVID-19 pandemic. Int J Clin Pract. 2021;75:e14490.
   PubMed Web of Science ®Google Scholar
• Bandari J, Maganty A, MacLeod LC, et al. Manufacturing and the market: rationalizing the shortage of Bacillus Calmette-Guérin. Eur Urol Focus. 2018;4:481–484.
   PubMedGoogle Scholar
• Balasubramanian A, Gunjur A, Weickhardt A, et al. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World J Urol. 2022;40:1111–1124.
   PubMed Web of Science ®Google Scholar
• Heer R, Lewis R, Duncan A, et al. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT. Health Technol Assess. 2022;26:1–144.
   PubMed Web of Science ®Google Scholar
• Catto JWF, Gordon K, Collinson M, et al. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study. J Clin Oncol. 2021;39:202–214.
   PubMed Web of Science ®Google Scholar
• Office for Health Improvement and Disparities. Cost utility analysis: health economic studies [Internet]. GOV.UK. 2020. [cited 2023 Mar 8]. Available from: https://www.gov.uk/guidance/cost-utility-analysis-health-economic-studies
   Google Scholar
• Clements MB, Atkinson TM, Dalbagni GM, et al. Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort. Eur Urol. 2022;81:294–304.
   PubMedGoogle Scholar
• Jung A, Nielsen ME, Crandell JL, et al. Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study. BJU Int. 2020;125:38–48.
   PubMed Web of Science ®Google Scholar
• Yang LS, Shan BL, Shan LL, et al. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol. 2016;25:281–297.
   PubMed Web of Science ®Google Scholar
• Rutherford C, Patel MI, Tait M-A, et al. Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. Qual Life Res. 2021;30:345–366.
   PubMedGoogle Scholar
• Tan WS, Teo CH, Chan D, et al. Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed-methods approach. BJU Int. 2020;125:669–678.
   PubMed Web of Science ®Google Scholar
• Taylor JM, Feifer A, Savage CJ, et al. Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer. BJU Int. 2012;109:855–859.
   PubMed Web of Science ®Google Scholar